Published online before print
September 5, 2007, 10.1183/09031936.00042107
Eur Respir J 2007; 30:1103-1110
Copyright ©ERS Journals Ltd 2007
A USA-based registry for pulmonary arterial hypertension: 1982–2006
T. Thenappan,
S. J. Shah,
S. Rich and
M. Gomberg-Maitland
Section of Cardiology, Dept of Medicine, University of Chicago, Chicago, IL, USA.
CORRESPONDENCE: M. Gomberg-Maitland, 5841 S Maryland Ave, MC 2016, Chicago, IL, 60637, USA. Fax: 1 7738341764. E-mail: mgomberg{at}medicine.bsd.uchicago.edu
Keywords: Aetiology, epidemiology, medications, pulmonary arterial hypertension, survival
Received: April 6, 2007
Accepted August 20, 2007
The aim of this study was to define the epidemiology of World Health Organization (WHO) Group I pulmonary arterial hypertension (PAH) in a large referral centre in the USA.
The Pulmonary Hypertension Connection registry, initiated in 2004, evaluated all patients in a single USA practice from 1982–2006. For comparison, the authors divided the group by incident versus prevalent cohorts, aetiology and by treatment era.
In total, 578 patients (77% female) aged 48±14 yrs were entered. Of these, 80% had class III or IV symptoms. Over time, connective tissue disease-associated PAH increased, while referrals for HIV remained low. One-third of patients were referred on calcium channel blocker therapy even though only 4.6% had an acute response to vasodilator challenge. When compared by treatment era, there were no differences in the severity of PAH. However, survival had improved over time, with a 1-yr survival of 85% in the incident cohort.
In the USA, pulmonary arterial hypertension patients are still referred to tertiary centres too late. Referral of connective tissue disease is increasing, while referral of HIV remains low. Inappropriate calcium channel blocker treatment is common. Survival rates have increased but remain low suggesting that prognosis is improving but PAH is still a progressive, fatal disease.
This article has been cited by other articles:

|
 |

|
 |
 
V. V. McLaughlin, D. B. Badesch, M. Delcroix, T. R. Fleming, S. P. Gaine, N. Galie, J. S. R. Gibbs, N. H. Kim, R. J. Oudiz, A. Peacock, et al.
End Points and Clinical Trial Design in Pulmonary Arterial Hypertension
J. Am. Coll. Cardiol.,
June 30, 2009;
54(1_Suppl_S):
S97 - S107.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Gomberg-Maitland
Something Subtle About Death: Isolated Systolic Pulmonary Pressure
Circulation,
May 26, 2009;
119(20):
2647 - 2649.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. V. McLaughlin, S. L. Archer, D. B. Badesch, R. J. Barst, H. W. Farber, J. R. Lindner, M. A. Mathier, M. D. McGoon, M. H. Park, R. S. Rosenson, et al.
ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association Developed in Collaboration With the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association
J. Am. Coll. Cardiol.,
April 28, 2009;
53(17):
1573 - 1619.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Writing Committee Members, V. V. McLaughlin, S. L. Archer, D. B. Badesch, R. J. Barst, H. W. Farber, J. R. Lindner, M. A. Mathier, M. D. McGoon, M. H. Park, et al.
ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: Developed in Collaboration With the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association
Circulation,
April 28, 2009;
119(16):
2250 - 2294.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Humbert
Update in Pulmonary Hypertension 2008
Am. J. Respir. Crit. Care Med.,
April 15, 2009;
179(8):
650 - 656.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Humbert
More pressure on pulmonary hypertension
Eur. Respir. Rev.,
March 1, 2009;
18(111):
1 - 3.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Souza and C. Jardim
Trends in pulmonary arterial hypertension
Eur. Respir. Rev.,
March 1, 2009;
18(111):
7 - 12.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. M. Kawut, N. Al-Naamani, C. Agerstrand, E. Berman Rosenzweig, C. Rowan, R. J. Barst, S. Bergmann, and E. M. Horn
Determinants of Right Ventricular Ejection Fraction in Pulmonary Arterial Hypertension
Chest,
March 1, 2009;
135(3):
752 - 759.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. W. Schrier and S. Bansal
Pulmonary Hypertension, Right Ventricular Failure, and Kidney: Different from Left Ventricular Failure?
Clin. J. Am. Soc. Nephrol.,
September 1, 2008;
3(5):
1232 - 1237.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Gomberg-Maitland
Traditional and Alternative Designs for Pulmonary Arterial Hypertension Trials
Proceedings of the ATS,
July 15, 2008;
5(5):
610 - 616.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. M. Chin and L. J. Rubin
Pulmonary arterial hypertension.
J. Am. Coll. Cardiol.,
April 22, 2008;
51(16):
1527 - 1538.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Humbert
Update in Pulmonary Arterial Hypertension 2007
Am. J. Respir. Crit. Care Med.,
March 15, 2008;
177(6):
574 - 579.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. L. Archer, M. Gomberg-Maitland, M. L. Maitland, S. Rich, J. G. N. Garcia, and E. K. Weir
Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1{alpha}-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer
Am J Physiol Heart Circ Physiol,
February 1, 2008;
294(2):
H570 - H578.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2007 by the European Respiratory Society.
|